title: Statin use and risk of basal cell carcinoma.
abstract: OBJECTIVE
  We examined the association between statin use and basal cell carcinoma (BCC) risk.
  
  
  METHODS
  We identified all members of a large integrated health care delivery system with a diagnosis of a histologically proven BCC in 1997. Subsequent BCCs were identified through 2006 from health plan electronic pathology records. Longitudinal exposure to statins and other lipid-lowering agents was determined from automated pharmacy records. We used extended Cox regression to examine the independent association between receipt of statin therapy (ever vs never, cumulative duration) and risk of subsequent BCC. To minimize confounding by indication, we conducted sensitivity analyses in the subset of individuals considered eligible for lipid-lowering therapy based on national guidelines.
  
  
  RESULTS
  Among 12,123 members given a diagnosis of BCC who had no prior statin exposure, 6381 developed a subsequent BCC during follow-up. Neither "ever use of statins" (adjusted hazard ratio 1.02, 95% confidence interval: 0.92-1.12) or cumulative duration of statin (adjusted hazard ratio 1.02/year, 95% confidence interval: 0.99-1.11) was associated with subsequent BCC after adjustment for age, sex, and health care use. Risk estimates did not change appreciably when the analysis was limited to the subset of individuals who met eligibility criteria for initiating statin therapy. There was also no significant association between use of non-statin antilipemics and subsequent BCC (adjusted hazard ratio 1.10, 95% confidence interval: 0.76-1.58).
  
  
  CONCLUSIONS
  No information was available for BCC risk factors, such as sun sensitivity and sun exposure.
  
  
  CONCLUSIONS
  Among a large cohort of individuals with BCC, statin therapy was not significantly associated with risk of subsequent BCC.
authors.affiliation: Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA. maryam.m.asgari@kp.org
authors.forename: Maryam M
authors.initials: MM
authors.lastname: Asgari
authors.forename: Jean
authors.initials: J
authors.lastname: Tang
authors.forename: Ervin H
authors.initials: EH
authors.lastname: Epstein
authors.forename: Mary-Margaret
authors.initials: MM
authors.lastname: Chren
authors.forename: E Margaret
authors.initials: EM
authors.lastname: Warton
authors.forename: Charles P
authors.initials: CP
authors.lastname: Quesenberry
authors.forename: Alan S
authors.initials: AS
authors.lastname: Go
authors.forename: Gary D
authors.initials: GD
authors.lastname: Friedman
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D002280:Basal Cell Carcinoma / Q000209:etiology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors